nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT04654689 | Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients | PHASE2 | COMPLETED | INTERVENTIONAL | false | Fundación Universidad Católica de Valencia San Vicente Mártir | Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of c... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Liposomed polyphenols resveratrol and curcumin"
},
{
"type": "OTHER",
"name": "Placebo for liposomed resveratrol and curcumin"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "Isocaloric Diet"
},
{
"type": "DRUG",
"name": "G04CB02"
},... | 2021-11-20 | https://clinicaltrials.gov/study/NCT04654689 | [
"oxidative_stress",
"glutamate_excitotoxicity",
"neuroinflammation"
] | [
{
"facility": "José Enrique de la Rubia Ortí",
"city": "Valencia",
"state": "Valencia",
"country": "Spain",
"status": "",
"lat": 39.47391,
"lon": -0.37966
}
] | {
"criteria": "Inclusion Criteria:\n\n* All ALS patients, over 18 years of age and with a clear diagnosis and symptomatology of ALS since at least 6 months.\n\nExclusion Criteria:\n\n* Women under 50 years of age and childbearing age.\n* Tracheotomy patients.\n* Patients with invasive or non-invasive ventilation with... | {
"compound": "Liposomed polyphenols (resveratrol and curcumin) with G04CB02",
"targeting_mechanism": "Combination of antioxidant polyphenols and an undefined agent (G04CB02) targeting oxidative stress and inflammation in ALS pathogenesis.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
... | ||
NCT07423494 | Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576) | PHASE1, PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10 | [
{
"type": "DRUG",
"name": "nL-CHCHD-001"
}
] | 2026-03 | https://clinicaltrials.gov/study/NCT07423494 | [
"CHCHD10"
] | [
{
"facility": "Mayo Clinic",
"city": "Rochester",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.02163,
"lon": -92.4699
}
] | {
"criteria": "Inclusion Criteria:\n\n* Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s)\n* Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to parti... | {
"compound": "nL-CHCHD-001",
"targeting_mechanism": "Personalized antisense oligonucleotide (ASO) designed to target pathogenic CHCHD10 variant in a single ALS patient.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurpos... | ||
NCT04516096 | A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS. | [
{
"type": "DRUG",
"name": "AMX0035"
}
] | 2020-11-22 | https://clinicaltrials.gov/study/NCT04516096 | [
"TARDBP"
] | [
{
"facility": "Forbes Norris MDA/ALS Research Center - California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Massachusetts General Hospital",
"city": "... | {
"criteria": "Inclusion Criteria:\n\n* Any patient who has completed follow-up in an Amylyx sponsored trial of AMX0035 for the treatment of ALS will be eligible to enroll into this Protocol\n* Capable of providing informed consent\n* Capable and willing to follow trial procedures\n* Capable and willing of travelling... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06177431 | An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease | PHASE1 | COMPLETED | INTERVENTIONAL | false | Neurizon Therapeutics Limited | This study is a multicenter, 12-month open label extension study, following Phase 1 Study MON-2021-001, with a single dose of monepantel (MPL) once daily (QD) for the treatment of individuals with MND. | [
{
"type": "DRUG",
"name": "Monepantel"
}
] | 2024-02-13 | https://clinicaltrials.gov/study/NCT06177431 | [
"pyruvate_dehydrogenase_kinase_inhibition"
] | [
{
"facility": "Macquarie University",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Calvary Health Care Bethlehem",
"city": "Melbourne",
"state": "Victoria",
"country": "Austral... | {
"criteria": "Inclusion Criteria:\n\n1. Signed informed consent obtained prior to initiation of any study specific procedures and treatment.\n2. Individuals who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n3. Able to swallow study drug tablets.\... | {
"compound": "Monepantel",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00420719 | Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS) | NA | UNKNOWN | INTERVENTIONAL | false | Synapse Biomedical | The overall goal of this research is to delay the respiratory decline of patients with Amyotrophic Lateral Sclerosis (ALS) thereby increasing their lifespan by conditioning the diaphragm with laparoscopically placed electrodes.
This device currently holds an Investigational Device Exemption No. G040142 in the United S... | [
{
"type": "DEVICE",
"name": "Intramuscular diaphragm electrodes"
}
] | 2004-10 | https://clinicaltrials.gov/study/NCT00420719 | [] | [
{
"facility": "Forbes Norris - California Pacific Medical Center (CPMC)",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Stanford University Medical Center",
"city": "Stanford",
... | {
"criteria": "Inclusion Criteria:\n\n* Age 18 or older\n* Participants with familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria will be eligible\n* Bilateral phrenic nerve function clinically acceptable as demo... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05095571 | A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study | NA | RECRUITING | INTERVENTIONAL | false | Haukeland University Hospital | Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there is no effective treatment. Care of advanced ALS will have a cost of 4-8 million NOK (Norwegian kroner) per year.
Research i.a. from t... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "EH301 (Nicotinamide Riboside/Pterostilbene)"
}
] | 2021-10-07 | https://clinicaltrials.gov/study/NCT05095571 | [
"nad_metabolism",
"histone_deacetylase_inhibition"
] | [
{
"facility": "Haukeland University Hospital",
"city": "Bergen",
"state": "",
"country": "Norway",
"status": "RECRUITING",
"lat": 60.39299,
"lon": 5.32415
},
{
"facility": "Nordlandssykehuset HF",
"city": "Bodø",
"state": "",
"country": "Norway",
"status": "NOT_YE... | +4755975063 | obty@haukeland.no | {
"criteria": "Inclusion Criteria:\n\n* Patients who fulfilled the criteria for the NO-ALS study and have completed the study will be proposed inclusion in the NO-ALS extension study protocol. Patients from both arm 1 and arm 2 in the NO-ALS study will be allowed inclusion in the prolongation study\n\nExclusion Crite... | {
"compound": "EH301 (Nicotinamide Riboside/Pterostilbene)",
"targeting_mechanism": "Increases NAD+ levels and histone deacetylation enzyme (sirtuin) activity to enhance mitochondrial proteostasis and neurogenesis in motor neurons.",
"targeting_mechanism_pmid": "31929756",
"animal_results": "Nicotinamide Ribosi... |
NCT00415519 | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III | PHASE3 | COMPLETED | INTERVENTIONAL | false | Shionogi | The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-cont... | [
{
"type": "DRUG",
"name": "MCI-186"
},
{
"type": "DRUG",
"name": "Placebo of MCI-186"
}
] | 2006-12-31 | https://clinicaltrials.gov/study/NCT00415519 | [
"oxidative_stress"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Patients who are defined as \"definite ALS,\" \"probable ALS\" or \"probable-laboratory-supported ALS,\" met diagnostic criteria revised EL Escorial for Airlie House.\n* Patients who cannot take at least one action of eating a meal, excreting, or moving with oneself alone, and ... | {
"compound": "MCI-186",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00353665 | Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | University of Lisbon | The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons), a drug used to treat Alzheimer´s disease, on the progression of Amyotrophic Lateral Sclerosis (ALS). Mema... | [
{
"type": "DRUG",
"name": "Memantine (Ebixa)"
},
{
"type": "DRUG",
"name": "riluzole"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2005-07 | https://clinicaltrials.gov/study/NCT00353665 | [
"GRIN1"
] | [
{
"facility": "Department of Neurology - Hospital de Santa Maria",
"city": "Lisbon",
"state": "",
"country": "Portugal",
"status": "",
"lat": 38.72509,
"lon": -9.1498
}
] | {
"criteria": "Inclusion Criteria:\n\n* Definite or probable disease - revise El Escorial criteria\n* Normal blood tests\n* Riluzole treatment during 1 month or more\n* EMG in accordance with El Escorial criteria\n\nExclusion Criteria:\n\n* Other diseases (such as PNP)\n* Both ADM muscles \\< 3 on MRC scale\n* Conduc... | {
"compound": "Memantine",
"targeting_mechanism": "Uncompetitive, moderate affinity NMDA receptor antagonist that binds to the NMDA receptor channel and regulates calcium influx into neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknow... | ||
NCT00355576 | Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Columbia University | The objective of this study is to compare two combinations of drugs, minocycline and creatine or celecoxib and creatine, in a phase II trial designed to determine which combination is more effective for ALS. | [
{
"type": "DRUG",
"name": "Celecoxib"
},
{
"type": "DRUG",
"name": "Creatine"
},
{
"type": "DRUG",
"name": "Minocycline"
}
] | 2006-07 | https://clinicaltrials.gov/study/NCT00355576 | [
"neuroinflammation",
"oxidative_stress"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "UCLA",
"city": "Los Angeles",
"state": "California",
"country": "United States",
... | {
"criteria": "Inclusion Criteria:\n\n* A clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS, according to modified EL Escorial criteria\n* FVC greater or equal to 60% at the screening visit\n* Symptom onset within 5 years\n* 21 to 85 years of age\n* If patients are taking riluzol... | {
"compound": "Celecoxib",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00397423 | G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response | PHASE2 | COMPLETED | INTERVENTIONAL | false | Peking University | This study will examine the effectiveness of G-CSF in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and motor cortex. Patients develop progressive wasting and weakness of both ... | [
{
"type": "DRUG",
"name": "Granulocyte Colony Stimulating Factor"
},
{
"type": "DRUG",
"name": "NS"
}
] | 2006-12 | https://clinicaltrials.gov/study/NCT00397423 | [
"neuroprotection"
] | [
{
"facility": "Dongsheng Fan",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | {
"criteria": "Inclusion Criteria:\n\n* All subjects must have a verifiable diagnosis of ALS of 0.5 to 2 years' duration. The diagnosis must be supported by the Revised Criteria of the World Federation of Neurology. The grades of diagnosis must be clinically definite ALS or clinically probable ALS.\n* All subjects mu... | {
"compound": "Granulocyte Colony Stimulating Factor (G-CSF)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03427086 | Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | American University of Beirut Medical Center | This is a randomized double blinded randomized 2:1 study. The duration of the study is 6 month. The safety and tolerability of high doses of biotin (300 mg/ day) will be compared to placebo in patients with amyotrophic lateral sclerosis. Patients will be evaluated at baseline, 3, and 6 month. The primary outcome will b... | [
{
"type": "DRUG",
"name": "Biotin"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2018-01-29 | https://clinicaltrials.gov/study/NCT03427086 | [
"biotin"
] | [
{
"facility": "American univeristy of Beirut medical center",
"city": "Beirut",
"state": "",
"country": "Lebanon",
"status": "",
"lat": 33.89332,
"lon": 35.50157
}
] | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed within 3 years prior to participation as having possible, probable, or definite ALS, either sporadic or familial according to modified El Escorial criteria\n* Age 18-80, able to provide informed consent, and compl... | {
"compound": "Biotin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01938495 | Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Barrow Neurological Institute | The study is being conducted to determine if DPS treatment for people with ALS and hypoventilation is associated with improved survival or diaphragm function.
The primary objective of the study is to conduct a multi-center, randomized controlled clinical trial comparing standard of care (control) to diaphragm stimulat... | [
{
"type": "DEVICE",
"name": "NeuRx® Diaphragm Pacing System™ (DPS)"
}
] | 2013-08 | https://clinicaltrials.gov/study/NCT01938495 | [
"neuromuscular_transmission"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": ... | {
"criteria": "Inclusion Criteria:\n\n1. Age 21 years or older.\n2. Sporadic or familial ALS diagnosed as definite, probable or possible ALS as defined by revised El Escorial criteria.\n3. Evidence of hypoventilation at Screening with at least one of the following:\n\n 1. Maximal static inspiratory pressure (MIP) \... | {
"compound": "NeuRx Diaphragm Pacing System (DPS)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00876772 | Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Charite University, Berlin, Germany | Amyotrophic Lateral Sclerosis (ALS) is an adult neurodegenerative disease that is caused by a selective degeneration of the motor nerve cells in the cortex and myelon. As a result of motor neurodegeneration, a progredient paralysis of the extremities and of the speaking, swallowing, and breathing musculature develops. ... | [
{
"type": "DRUG",
"name": "Olanzapine"
}
] | 2011-03 | https://clinicaltrials.gov/study/NCT00876772 | [
"olanzapine"
] | [
{
"facility": "Charité - Universitätsmedizin, Berlin, Germany",
"city": "Berlin",
"state": "",
"country": "Germany",
"status": "",
"lat": 52.52437,
"lon": 13.41053
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years old\n* Clinical diagnosis of definitive, probable, and possible ALS (revised El Escorial Criteria) or diagnosis of the clinical ALS-variants of Progressive Muscle Atrophy (PMA)\n* Sporadic and familial ALS\n* Beginning of symptoms of... | {
"compound": "Olanzapine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00004771 | Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease | PHASE2 | COMPLETED | INTERVENTIONAL | false | National Center for Research Resources (NCRR) | OBJECTIVES:
I. Evaluate the effects of androgen suppression with leuprolide and androgen replacement with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor neuron disease. | [
{
"type": "DRUG",
"name": "leuprolide"
},
{
"type": "DRUG",
"name": "testosterone"
}
] | 1992-10 | https://clinicaltrials.gov/study/NCT00004771 | [
"Androgen receptor"
] | [] | {
"criteria": "PROTOCOL ENTRY CRITERIA:\n\n--Disease Characteristics--\n\nMen aged 18 and over with motor neuron disease, i.e.:\n\n* X-linked spinal and bulbar muscular atrophy (Kennedy's disease)\n* Confirmed by androgen receptor, exon-1 mutation genotype\n* Amyotrophic lateral sclerosis\n* Spinal muscular atrophy\n... | {
"compound": "leuprolide and testosterone",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05860244 | Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Preclinical and clinical data strongly suggest that administration of salbutamol in ALS patients may improve walking capacity related to motor fatigue by enhancing neuromuscular transmission. Salbutamol may exert a neuroprotective effect and slow down the progression of clinical signs and symptoms. The main objective o... | [
{
"type": "DRUG",
"name": "Salbutamol"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2024-09 | https://clinicaltrials.gov/study/NCT05860244 | [
"neuromuscular_transmission"
] | [
{
"facility": "Hôpital Pitié Salpêtrière",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | 01 42 16 58 70 | g.querin@institut-myologie.org | {
"criteria": "Inclusion Criteria:\n\n* Subjects who meet the revised El Escorial criteria for probable or definite sporadic ALS\n* Adult patients between 18 and 75 years of age\n* Patients who are ambulatory and able to perform the 6MWT and quantitative muscle testing at screening (ALSFRS-R-walking = 3)\n* Patients ... | {
"compound": "Salbutamol",
"targeting_mechanism": "β2-adrenergic agonist that enhances neuromuscular transmission and may exert neuroprotective effects.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | PHASE3 | TERMINATED | INTERVENTIONAL | false | Alexion Pharmaceuticals, Inc. | The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS. | [
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "BIOLOGICAL",
"name": "Ravulizumab"
}
] | 2020-03-30 | https://clinicaltrials.gov/study/NCT04248465 | [
"complement_pathway"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Neuromuscular Research Center and Clinic",
"city": "Phoenix",
"state": "Arizona",
"coun... | {
"criteria": "Key Inclusion Criteria:\n\n1. A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria (possible, laboratory-supported probable, probable, or definite ALS).\n2. ALS onset ≤ 36 months from Screening.\n3. Documented meningococcal vaccination not more than 3 years prior to, or at the t... | {
"compound": "Ravulizumab",
"targeting_mechanism": "Complement cascade inhibitor targeting the complement system's role in motor neuron degeneration.",
"targeting_mechanism_pmid": "27056040",
"animal_results": "Complement activation has been found in animal models of ALS, including the SOD1G93A mouse model, wi... | ||
NCT03690791 | Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease | PHASE3 | UNKNOWN | INTERVENTIONAL | false | Gold Coast Hospital and Health Service | This is a randomised, double-blind, placebo controlled study on a cannabis-based medicine extract (MediCabilis CBD Oil), in patients with Amyotrophic Lateral Sclerosis or Motor Neurone Disease. Participants will be randomised in a 1:1 ratio to receive MediCabilis CBD Oil or placebo oil. The treatment duration is 6 mont... | [
{
"type": "DRUG",
"name": "MediCabilis CBD Oil"
},
{
"type": "DRUG",
"name": "Placebo Oil"
}
] | 2019-01-09 | https://clinicaltrials.gov/study/NCT03690791 | [
"Cannabinoid receptor"
] | [
{
"facility": "Gold Coast Hospital and Health Service",
"city": "Gold Coast",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -28.00029,
"lon": 153.43088
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Affected by ALS/MND, either of definite or probable according to the El Escorial revised criteria\n2. Can provide written informed consent\n3. Able and willing to comply with all study requirement\n4. Male or female, ages 25-80 years old\n5. Onset of first symptom within the l... | {
"compound": "MediCabilis CBD Oil",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06230562 | DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease | NA | UNKNOWN | INTERVENTIONAL | false | University Hospital, Tours | In response to oxidative stress, cells activate the Nrf-2 pathway, which induces translation of its target genes and corresponding proteins involved in the antioxidant response. This explains the interest in the Nrf-2 pathway in the pathophysiology of Amyotrophic lateral sclerosis (ALS), supported by the results of sev... | [
{
"type": "BIOLOGICAL",
"name": "Blood sample"
},
{
"type": "BIOLOGICAL",
"name": "Blood sample"
}
] | 2024-02 | https://clinicaltrials.gov/study/NCT06230562 | [
"TARDBP",
"NFE2L2",
"oxidative_stress"
] | [] | +33247474665 | e.mousset@chu-tours.fr | {
"criteria": "Patients group :\n\nInclusion Criteria:\n\n* Men and women ≥ 18 years old\n* Person affiliated to a French social security scheme or equivalent\n* ALS diagnosed according to El Escorial criteria\n* Diagnosis of ALS \\< 6 months\n* Onset of symptoms \\< 2 years\n* Signed informed consent\n\nNon-inclusio... | {
"compound": "unknown",
"targeting_mechanism": "The Nrf-2 pathway in response to oxidative stress, modulated by TDP-43, to induce antioxidant proteins.",
"targeting_mechanism_pmid": "34663413",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": "... |
NCT02469896 | A Trial of Tocilizumab in ALS Subjects | PHASE2 | COMPLETED | INTERVENTIONAL | false | Barrow Neurological Institute | This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS). The investigators also want to find out if tocilizumab is safe to take without causing too many side effects.
Currently ALS has no cure and 2 modestly effective treatment to slow the... | [
{
"type": "DRUG",
"name": "Tocilizumab"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2015-11 | https://clinicaltrials.gov/study/NCT02469896 | [
"IL-6"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of Kansas Medical Center",
"city": "Kansas City",
"state": "Kansas",
"countr... | {
"criteria": "Inclusion Criteria:\n\n* Participants with ALS (El Escorial criteria: possible, laboratory-supported probable, probable or definite)\n* Capable of providing informed consent and complying with trial procedures.\n* High inflammatory profile of PBMC gene expression\n* Upright SVC ≥40% of predicted value ... | {
"compound": "Tocilizumab",
"targeting_mechanism": "IL-6 receptor antagonist that inhibits the immune-mediated death of motor neurons.",
"targeting_mechanism_pmid": "28612258",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05542576 | Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Amydis Inc. | The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS). | [
{
"type": "DRUG",
"name": "AMDX2011P"
}
] | 2022-08-24 | https://clinicaltrials.gov/study/NCT05542576 | [
"amyloidogenic_proteinopathy"
] | [
{
"facility": "Eye Research Foundation",
"city": "Newport Beach",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.61891,
"lon": -117.92895
},
{
"facility": "Brittany NIcholl",
"city": "Pasadena",
"state": "California",
"country": "United Sta... | {
"criteria": "Inclusion Criteria:\n\nFor Subjects with Parkinson's Disease\n\n1. Clinically established Parkinson's disease based on Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's disease (Table 8) and a modified Hoehn \\& Yahr scale of 1-3 (Table 9).\n2. No suspected atypical parkinson... | {
"compound": "AMDX-2011P",
"targeting_mechanism": "Retinal tracer for imaging amyloidogenic proteinopathy in neurodegenerative diseases.",
"targeting_mechanism_pmid": "36834792",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02548663 | Sport Therapy and Osteopathy Manipulative Treatment in ALS | NA | COMPLETED | INTERVENTIONAL | false | University of Milano Bicocca | This project assessed muscle oxidative metabolism and fatigue in patients affected by amyotrophic lateral sclerosis (ALS) undergoing to three months of individualized cardiovascular and strength training. Muscle oxidative metabolism and strength will be assessed by non-invasive methods, such as near-infrared spectrosco... | [
{
"type": "OTHER",
"name": "Sport therapy"
},
{
"type": "OTHER",
"name": "Osteopathic treatment"
}
] | 2014-06 | https://clinicaltrials.gov/study/NCT02548663 | [
"oxidative_stress"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* diagnosis of ALS\n* early stages of disease\n* able to perform exercise with major muscle groups.\n\nExclusion Criteria:\n\n* non-invasive ventilation (NIV)\n* tracheostomy\n* coronaropathy\n* ongoing infectious diseases\n* cognitive deficits.",
"sex": "ALL",
"min_age": "18... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00140452 | Phase II Study Using Thalidomide for the Treatment of ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Dartmouth-Hitchcock Medical Center | The use of Thalidomide in patients with ALS who have disease progression. | [
{
"type": "DRUG",
"name": "Thalidomide"
}
] | 2005-02 | https://clinicaltrials.gov/study/NCT00140452 | [
"TNF-alpha",
"angiogenesis"
] | [
{
"facility": "Dartmouth Hichcock Medical Center",
"city": "Lebanon",
"state": "New Hampshire",
"country": "United States",
"status": "",
"lat": 43.64229,
"lon": -72.25176
}
] | {
"criteria": "Inclusion Criteria:\n\n* Clinically proven ALS\n* Disease duration less than or equal to 5 years\n* ALSFRS-R score equal to or greater then 30\n\nExclusion Criteria:\n\n* Patients with known deep venous thrombosis or hyper coagulable state will be excluded\n* Patients with FVC less than 80%",
"sex": ... | {
"compound": "Thalidomide",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03127514 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS. | [
{
"type": "DRUG",
"name": "AMX0035"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2017-06-22 | https://clinicaltrials.gov/study/NCT03127514 | [
"TARDBP",
"FUS"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "UC Irvine Medical Center",
"city": "Orange",
"state": "California",
"country": "United ... | {
"criteria": "Key Inclusion Criteria:\n\n1. Male or female, aged 18-80 years of age\n2. Sporadic or familial ALS diagnosed as definite as defined by the World Federation of Neurology revised El Escorial criteria\n3. Less than or equal to 18 months since ALS symptom onset\n4. Capable of providing informed consent and... | {
"compound": "AMX0035",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02152449 | Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Limoges | The purpose of this study is to determine whether an early oral nutritional supplementation (ONS) in amyotrophic lateral sclerosis (ALS) patients is effective on the treatment of this rapidly progressive disease. | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "Oral nutritional supplementation"
}
] | 2014-07 | https://clinicaltrials.gov/study/NCT02152449 | [
"nutritional_status"
] | [
{
"facility": "Service de Neurologie",
"city": "Limoges",
"state": "",
"country": "France",
"status": "",
"lat": 45.83362,
"lon": 1.24759
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients ≥18 years of age, diagnosed with ALS (\\<2 months before inclusion) according to Airlie House criteria : definite, probable, or probable laboratory supported;\n* Time between first symptoms and diagnosis less than 18 months\n* Sporadic or familial cases\n* Patient agre... | {
"compound": "Oral nutritional supplementation",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00386464 | Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Johns Hopkins University | Non-invasive ventilation or BiPAP®, which is a form of breathing support delivered through a facemask, is a successful treatment for the respiratory complications of amyotrophic lateral sclerosis (ALS). It has been shown to prolong survival, improve quality of life, and improve cognitive function. It is widely used amo... | [
{
"type": "DEVICE",
"name": "noninvasive positive pressure ventilation"
}
] | 2002-04 | https://clinicaltrials.gov/study/NCT00386464 | [] | [
{
"facility": "Johns Hopkins University School of Medicine",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
}
] | {
"criteria": "Inclusion Criteria:\n\n* Probable or definite ALS by El Escorial criteria\n* age \\>17 years\n* FVC \\>60\n* minimal respiratory symptoms (no orthopnea or dyspnea at rest)\n* ability to provide informed consent\n\nExclusion Criteria:\n\n* Presence of another neurodegenerative disease\n* arterial CO2 ab... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05797701 | A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Sanofi | Part 1:
This is an open label, balanced randomized, single dose, 2-sequence, 2-period (period 1 and period 2), 2-treatment crossover (between Treatment A and Treatment B for Part 1), study part to determine the relative bioavailability of SAR443820 in tablet formulation versus capsule formulation under fasted conditio... | [
{
"type": "DRUG",
"name": "SAR443820"
},
{
"type": "DRUG",
"name": "SAR443820"
}
] | 2021-07-28 | https://clinicaltrials.gov/study/NCT05797701 | [] | [
{
"facility": "Prism Research-Site Number:8400001",
"city": "Saint Paul",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.94441,
"lon": -93.09327
}
] | {
"criteria": "Inclusion Criteria:\n\n* Male or female participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring\... | {
"compound": "SAR443820",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06829212 | Research on Wireless Brain Implant System for General Control of External Devices | NA | RECRUITING | INTERVENTIONAL | false | Shanghai StairMed Technology Co., Ltd. | The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external devices, such as a cursor and other assistive technologies, for paralyzed and amputee patients.
WRS integrates a high-throughput, ultra-flex... | [
{
"type": "DEVICE",
"name": "WRS"
}
] | 2025-03 | https://clinicaltrials.gov/study/NCT06829212 | [] | [
{
"facility": "Huashan Hospital Affiliated to Fudan University",
"city": "Shanghai",
"state": "Shanghai Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 31.22222,
"lon": 121.45806
}
] | 021-80510178 | kongcen@stairmed.com | {
"criteria": "Inclusion Criteria:\n\n* Aged 18-80 years (inclusive), any gender.\n* Diagnosed with spinal cord injury, brainstem stroke, amyotrophic lateral sclerosis, or other motor neuron diseases causing partial or complete paralysis, or bilateral upper limb amputation.\n* Diagnosis stable for at least 6 months b... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04744532 | iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Kyoto University | This study consists of a phase 1 part and a phase 2 part.
Phase 1 part:
This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended phase 2 dose (RP2D) of bosutinib for treatment of ALS patients. ... | [
{
"type": "DRUG",
"name": "Bosutinib (Phase 1 part)"
},
{
"type": "DRUG",
"name": "Bosutinib (Phase 2 part)"
}
] | 2019-03-19 | https://clinicaltrials.gov/study/NCT04744532 | [
"SRC"
] | [
{
"facility": "Hiroshima University",
"city": "Hiroshima",
"state": "",
"country": "Japan",
"status": "",
"lat": 34.4,
"lon": 132.45
},
{
"facility": "Nara Medical University",
"city": "Kashihara",
"state": "",
"country": "Japan",
"status": "",
"lat": 34.58333... | {
"criteria": "\\[Phase 1 part\\]\n\nInclusion criteria:\n\n1. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. To be additionaly signed by a delegate signer if the subject is unable to handwrite.\n2. Patients aged... | {
"compound": "Bosutinib",
"targeting_mechanism": "inhibition of the Src/c-Abl pathway",
"targeting_mechanism_pmid": "28539470",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07006571 | At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis | NA | RECRUITING | INTERVENTIONAL | false | University of Trieste | Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that causes gradual muscle weakness and loss of muscle mass. It affects all muscles that control movement, speech, swallowing, and breathing. Unfortunately, ALS is currently incurable, and treatments are limited. Only two medications, riluzole an... | [
{
"type": "DEVICE",
"name": "Real tDCS"
},
{
"type": "DEVICE",
"name": "Sham tDCS"
}
] | 2025-05-19 | https://clinicaltrials.gov/study/NCT07006571 | [
"corticospinal_tract"
] | [
{
"facility": "Clinica Neurologica, Azienda Sanitaria Universitaria Giuliano Isontina",
"city": "Trieste",
"state": "Trieste",
"country": "Italy",
"status": "RECRUITING",
"lat": 45.64953,
"lon": 13.77678
}
] | +39 0403994282 | benussialberto@gmail.com | {
"criteria": "Inclusion Criteria:\n\n* Male or female patients with a probable, laboratory-supported diagnosis of ALS, or defined ALS according to current clinical criteria\n* Age greater than 18 years\n* Onset of disease ≤ 24 months\n* Disease progression in the last 3 months\n* A score ≥ 2 on the \"respiratory fai... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03076632 | Interactions Between Neurostimulation and Physical Exercise | NA | WITHDRAWN | INTERVENTIONAL | false | Bronx VA Medical Center | * People with cervical spinal cord injury (SCI) and amyotrophic lateral sclerosis (ALS) have reduced connections in the nerve circuits between the brain and the hands. Activating spared nerve circuits is one potential way to improve recovery.
* The investigators are testing different combinations of physical wrist and ... | [
{
"type": "DEVICE",
"name": "Cervical plus transcranial stimulation"
},
{
"type": "DEVICE",
"name": "Cervical stimulation plus hand/wrist exercise"
},
{
"type": "DEVICE",
"name": "Electromyographic (EMG)-triggered (closed-loop) stimulation"
}
] | 2017-04-01 | https://clinicaltrials.gov/study/NCT03076632 | [
"neural_circuit_activation"
] | [] | {
"criteria": "Inclusion Criteria:\n\n1. Age between 21 and 65 years;\n2. Chronic (more than 12 months since injury) incomplete SCI between levels C2-C8 or diagnosis of definite or probable ALS;\n3. Incomplete weakness of left or right hand muscles: score of 2, 3, or 4 (out of 5) on manual muscle testing of finger ex... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03321487 | Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | InSightec | The purpose of this study is to evaluate the safety, tolerability, and feasibility of Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DEVICE",
"name": "Blood-Brain Barrier opening with MRgFUS"
}
] | 2018-04-13 | https://clinicaltrials.gov/study/NCT03321487 | [
"blood_brain_barrier_permeability"
] | [
{
"facility": "Sunnybrook Health Sciences Centre",
"city": "Toronto",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 43.70643,
"lon": -79.39864
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosed with laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria (Brooks et al. 2000).\n2. Right-hand dominant male or female aged 18 years or older.\n3. Capable of providing informed ... | {
"compound": "MR-guided focused ultrasound (MRgFUS) with ultrasound contrast agent",
"targeting_mechanism": "MR-guided focused ultrasound opens the blood-brain barrier to enable delivery of therapeutic agents to the central nervous system.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"anima... | ||
NCT06069934 | A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2) | Expanded Access | NO_LONGER_AVAILABLE | EXPANDED_ACCESS | true | Prilenia | Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials. | [
{
"type": "DRUG",
"name": "Pridopidine"
}
] | https://clinicaltrials.gov/study/NCT06069934 | [
"D2 dopamine receptor"
] | [
{
"facility": "University of Alabama at Birmingham",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "",
"lat": 33.52066,
"lon": -86.80249
},
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country... | {
"criteria": "Inclusion Criteria Amyotrophic Lateral Sclerosis (ALS):\n\n* Sporadic or familial ALS.\n* Patient does not qualify for clinical trials of pridopidine or as per site investigator's opinion, and is not medically or geographically suitable for other clinical trials.\n* Capable of providing informed consen... | {
"compound": "Pridopidine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |||
NCT02874209 | Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique Hopitaux De Marseille | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the central and peripheral motor neurons, characterized by the rapidity of its evolution (median survival of 3 years). The pathophysiology of the disease is still poorly understood. Neuronal death results from several cellular mechanisms entan... | [
{
"type": "OTHER",
"name": "sodium MRI"
}
] | 2015-09 | https://clinicaltrials.gov/study/NCT02874209 | [
"neuronal_sodium_homeostasis"
] | [
{
"facility": "Assistance Publique Hopitaux de Marseille",
"city": "Masreille",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": null,
"lon": null
}
] | aude.grapperon@ap-hm.fr | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic lateral sclerosis patient according to the El Escorial criteria revised Brooks et al. 2000 bulbar or spinal beginning\n\nExclusion Criteria:\n\n* patient or healthy volonteer presenting MRI contre indications to this exam.\n* patient or healthy volonteer presenting ... | {
"compound": "unknown",
"targeting_mechanism": "Sodium MRI measures intracellular sodium accumulation as a biomarker of neuronal dysfunction and neuronal death in motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
... | |
NCT05959850 | A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS | PHASE2 | UNKNOWN | INTERVENTIONAL | false | The Florey Institute of Neuroscience and Mental Health | Ambroxol is a simple cough medicine that is predicted to slow ALS disease progression. This study aims to investigate if ambroxol in high doses is effective in treating ALS. This study will be carried out across 5 research sites in Australia (2 NSW, 1 VIC, 1 SA and 1 TAS), where newly diagnosed ALS patients will be ask... | [
{
"type": "DRUG",
"name": "Ambroxol"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2023-06-13 | https://clinicaltrials.gov/study/NCT05959850 | [
"Glucocerebrosidase"
] | [
{
"facility": "Brain and Mind Centre",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "RECRUITING",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Concord Repatriation General Hospital",
"city": "Sydney",
"state": "New South Wales",
... | +61 3 9035 6521 | bradley.turner@florey.edu.au | {
"criteria": "Inclusion Criteria:\n\n1. Must have given written informed consent before any study related assessments are performed and must be able to understand purpose of the study, including any possible risks and adverse events.\n2. ALS as diagnosed according to the recently proposed Gold Coast diagnostic crite... | {
"compound": "Ambroxol",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT05409508 | Psychological Management by Meditation of Full COnscience in Virtual REality of People With Amyotrophic Lateral Sclerosis: Effects on Cognition, Behavior, Quality of Life and Psychological Well-being | NA | WITHDRAWN | INTERVENTIONAL | false | University Hospital, Angers | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in progressive paralysis of the muscles involved in voluntary motor skills, speech, swallowing and breathing. It also causes non-motor symptoms including psychological, cognitive and behavioral difficulties that have a negative impact on pa... | [
{
"type": "OTHER",
"name": "mindfulness meditation care"
},
{
"type": "OTHER",
"name": "no mindfulness meditation care"
}
] | 2022-05 | https://clinicaltrials.gov/study/NCT05409508 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n* Majors to inclusion\n* Mother tongue: French\n* Patients for whom ALS of bulbar or spinal form defined according to El Escorial criteria is possible, probable or certain\n* Able to carry out the investigations and interventions provided for in the protocol\n* Signature of infor... | {
"compound": "unknown",
"targeting_mechanism": "Mindfulness meditation delivered in virtual reality targets psychological, cognitive, and behavioral non-motor symptoms of ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"r... | ||
NCT03241784 | Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | The Methodist Hospital Research Institute | Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS. | [
{
"type": "BIOLOGICAL",
"name": "Autologous T-regulatory lymphocytes"
},
{
"type": "BIOLOGICAL",
"name": "Interleukin-2"
}
] | 2016-05-16 | https://clinicaltrials.gov/study/NCT03241784 | [
"immune_regulation",
"IL2"
] | [
{
"facility": "Methodist Neurological Institute",
"city": "Houston",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 29.76328,
"lon": -95.36327
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1).\n3. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of ri... | {
"compound": "Autologous T-regulatory lymphocytes and Interleukin-2",
"targeting_mechanism": "Regulatory T cells exert immunomodulatory and neuroprotective effects to attenuate neuroinflammation in ALS.",
"targeting_mechanism_pmid": "32484719",
"animal_results": "unknown",
"animal_results_pmid": "",
"repur... | ||
NCT04165850 | Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | NeuroSense Therapeutics Ltd. | This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity). | [
{
"type": "DRUG",
"name": "Fixed dose combination Ciprofloxacin/Celecoxib"
}
] | 2019-11-25 | https://clinicaltrials.gov/study/NCT04165850 | [
"PTGS2",
"neuroinflammation"
] | [
{
"facility": "Sourasky Medical Center",
"city": "Tel Aviv",
"state": "",
"country": "Israel",
"status": "",
"lat": 32.08088,
"lon": 34.78057
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an Informed Consent Form (ICF)\n2. Males or females between the ages of 18 and 75 years of age, inclusive\n3. Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for ... | {
"compound": "Ciprofloxacin/Celecoxib fixed dose combination",
"targeting_mechanism": "Combination targeting neuroinflammation through antibiotic and anti-inflammatory mechanisms to address persistent CNS inflammation in ALS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_resu... | ||
NCT03103815 | Trial of Amivita in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | Wujin People's Hospital | The primary objectives of this study are to determine the safety and efficacy of Amivita, a compound of amino acids and vitamines in patients with Amyotrophic lateral sclerosis (ALS)ALS. The secondary objectives are to measure quality of life before and during intervention. This is a self-controlled clinical trial. Twe... | [
{
"type": "DRUG",
"name": "Amivita"
}
] | 2017-04-24 | https://clinicaltrials.gov/study/NCT03103815 | [
"oxidative_stress"
] | [
{
"facility": "Wujing People's Hospital",
"city": "Changzhou",
"state": "Jiangsu",
"country": "China",
"status": "RECRUITING",
"lat": 31.77359,
"lon": 119.95401
}
] | 86-519-85579128 | 513325835@qq.com | {
"criteria": "Inclusion Criteria\n\n* Patients must be men or women between the ages of 18 and 70 years\n* Patient is clinical definite or probable ALS by the hospitals listed in the protocol\n* Women who are of child bearing potential must have a negative pregnancy test\n* Willing to comply with the study visits\n*... | {
"compound": "Amivita",
"targeting_mechanism": "Amino acids and vitamins combination addressing oxidative stress and antioxidant system dysfunction in ALS.",
"targeting_mechanism_pmid": "34663413",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid... |
NCT03843710 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Clene Nanomedicine | REPAIR-ALS is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Amyotrophic Lateral Sclerosis (ALS) within twelve (12) months of Screening. The... | [
{
"type": "DRUG",
"name": "Gold Nanocrystals"
}
] | 2020-03 | https://clinicaltrials.gov/study/NCT03843710 | [
"oxidative_stress",
"neuronal_redox_state"
] | [
{
"facility": "UT Southwestern",
"city": "Dallas",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 32.78306,
"lon": -96.80667
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Able to understand and give written informed consent.\n2. Male or female patients aged 35 years or greater (inclusive) and less than 75 years of age at the time of ALS diagnosis.\n3. Patients with a confirmed ALS diagnosis: \"definite ALS\" or \"probable ALS\" or \"possible\" ... | {
"compound": "Gold Nanocrystals (CNM-Au8)",
"targeting_mechanism": "Gold nanocrystals restore impaired neuronal redox state by targeting NAD+:NADH ratio imbalance and oxidative stress in ALS.",
"targeting_mechanism_pmid": "34198557",
"animal_results": "ASC-Exosomes delayed disease progression in SOD1(G93A) mic... | ||
NCT05039268 | 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Macquarie University, Australia | Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "3K3A-APC Protein"
}
] | 2021-11-25 | https://clinicaltrials.gov/study/NCT05039268 | [
"PAR1",
"neuroprotection"
] | [
{
"facility": "Macquarie University",
"city": "Macquarie Park",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.78105,
"lon": 151.12757
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Patients must have clinically definite ALS (Awaji Criteria)\n2. Male or female age 18 years and less than 75 years at time of ALS study\n3. Symptom onset less than 36 months before screening\n4. Diagnosis of ALS less than 24 months before screening\n5. Clinically definite Uppe... | {
"compound": "3K3A-APC Protein",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04569435 | Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Annexon, Inc. | This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS. | [
{
"type": "DRUG",
"name": "ANX005"
}
] | 2021-01-15 | https://clinicaltrials.gov/study/NCT04569435 | [
"C3"
] | [
{
"facility": "Annexon Investigational Site 04",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Annexon Investigational Site 01",
"city": "Orange",
"state": "California",
"country":... | {
"criteria": "Key Inclusion Criteria:\n\n* Diagnosis of ALS according to the World Federation of Neurology revised EI Escorial criteria.\n* Onset of weakness within 3 years prior to Day 1 visit.\n* Slow Vital Capacity ≥ 50% of predicted normal adjusted for sex, age, and height (from the sitting position).\n* ALS Fun... | {
"compound": "ANX005",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 71